Nyxoah Aktie
WKN DE: A2QCWK / ISIN: BE0974358906
30.09.2022 22:30:00
|
Information on the total number of voting rights and shares
REGULATED INFORMATION
Mont-Saint-Guibert (Belgium), September 30, 2022, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the belowinformation following the issue of new shares.
- Share capital: EUR 4,440,069.16
- Total number of securities carrying voting rights: 25,846,279 (all ordinary shares)
- Total number of voting rights (= denominator): 25,846,279 (all relating to ordinary shares)
- Number of rights to subscribe to securities carrying voting rights not yet issued:
-
- 55 "2016 ESOP Warrants” issued on November 3, 2016, entitling their holders to subscribe to a total number of 27,500 securities carrying voting rights (all ordinary shares);
- 100 "2018 ESOP Warrants” issued on December 12, 2018, entitling their holders to subscribe to a total number of 50,000 securities carrying voting rights (all ordinary shares);
- 460,500 "2020 ESOP Warrants” issued on February 21, 2020, entitling their holders to subscribe to a total number of 460,500 securities carrying voting rights (all ordinary shares); and
- 1,378,125 "2021 ESOP Warrants” issued on September 8, 2021, entitling their holders to subscribe to a total number of 1,378,125 securities carrying voting rights (all ordinary shares).
*
* *
For further information, please contact:
Nyxoah
Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com
+1 917 749 1494
Attachment


Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Nyxoah S.A. Registered Shsmehr Nachrichten
26.03.25 |
EQS-News: Nyxoah erhält Approvable Letter für sein Genio®-System von der FDA (EQS Group) | |
26.03.25 |
EQS-News: FDA Issues Nyxoah an Approvable Letter for its Genio® System (EQS Group) | |
13.03.25 |
EQS-News: Nyxoah gibt Finanzergebnisse für das vierte Quartal und das Geschäftsjahr 2024 bekannt und informiert über die Unternehmensentwicklung (EQS Group) | |
13.03.25 |
EQS-News: Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating Results (EQS Group) | |
12.03.25 |
Ausblick: Nyxoah vermeldet Zahlen zum jüngsten Quartal (finanzen.net) | |
26.02.25 |
Erste Schätzungen: Nyxoah gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net) | |
19.02.25 |
EQS-News: Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle East (EQS Group) | |
19.02.25 |
EQS-News: Nyxoah gibt die Markteinführung der innovativen Genio®-Therapie im Nahen Osten bekannt (EQS Group) |
Analysen zu Nyxoah S.A. Registered Shsmehr Analysen
Aktien in diesem Artikel
Nyxoah S.A. Registered Shs | 7,02 | -9,07% |
|